Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tilia cordata pollen is a biological allergen extract derived from the pollen of the small-leaved linden tree (*Tilia cordata*). It is primarily utilized as a diagnostic tool in clinical settings to identify hypersensitivity and allergic sensitivities in patients suspected of having seasonal pollinosis or other allergic reactions to linden pollen. As an allergen extract, it works by eliciting a localized immune response (typically via skin prick testing or intradermal injection) in sensitized individuals, allowing for the diagnosis of specific IgE-mediated allergies. It is categorized as a biologic and is documented in pharmaceutical databases like DrugBank (DB10954).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tilia cordata pollen.